【24h】

Preparation and evaluation of a new erythromycin derivative -- erythromycin taurate.

机译:一种新的红霉素衍生物-牛磺酸红霉素的制备和评估。

获取原文
获取原文并翻译 | 示例
           

摘要

Erythromycin taurate, a new derivative of erythromycin, was prepared by reacting erythromycin base with tauric acid and its physico-chemical and biological properties were evaluated. The derivative has reasonably good solubility in organic solvents. The partition coefficient values in chloroform/water 1.17 and octanol/water 1.16 systems indicate its good distribution in various tissues in vivo. The in vitro antimicrobial potency of the derivative (833.33 microg mg(-1)) is higher than that of the existing derivatives such as erythromycin estolate, erythromycin stearate, erythromycin ethyl succinate, erythromycin gluceptate, erythromycin lactobionate. The antimicrobial spectrum is comparable to that of the parent compound. Our results indicate that erythromycin taurate has a high potential for possible clinical application and is more efficient against Escherichia coli and Klebsiella pneumoniae than the parent base.
机译:通过使红霉素碱与牛磺酸反应制备了红霉素的新衍生物牛磺酸红霉素,并对其理化和生物学性质进行了评价。该衍生物在有机溶剂中具有相当好的溶解性。在氯仿/水1.17和辛醇/水1.16系统中的分配系数值表明其在体内各种组织中的分布良好。该衍生物的体外抗菌能力(833.33 microg mg(-1))高于现有衍生物如estolate红霉素,erythromycin硬脂酸酯,erythromycin琥珀酸乙酯,erythromycin葡糖酸酯,erythromycin乳糖酸。抗菌谱与母体化合物相当。我们的结果表明,牛磺酸红霉素具有较高的潜在临床应用价值,并且比亲本碱对大肠杆菌和肺炎克雷伯菌更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号